O	0	6	Plasma
O	7	10	TNF
O	10	11	-
O	11	12	α
O	13	16	and
O	17	24	Soluble
O	25	28	TNF
O	29	37	Receptor
O	38	44	Levels
O	45	50	after
B-intervention	51	62	Doxorubicin
I-intervention	63	67	with
I-intervention	68	70	or
I-intervention	71	78	without
I-intervention	79	81	Co
I-intervention	81	82	-
I-intervention	82	96	Administration
I-intervention	97	99	of
I-intervention	100	105	Mesna
O	105	106	-
O	106	107	A
O	108	118	Randomized
O	118	119	,
O	120	125	Cross
O	125	126	-
O	126	130	Over
O	131	139	Clinical
O	140	145	Study
O	145	146	.

O	147	159	Chemotherapy
O	159	160	-
O	160	167	induced
O	168	177	cognitive
O	178	188	impairment
O	189	190	(
O	190	194	CICI
O	194	195	)
O	196	198	is
O	199	200	a
O	201	207	common
O	208	216	sequelae
O	217	219	of
O	220	226	cancer
O	227	234	therapy
O	234	235	.

O	236	242	Recent
O	243	254	preclinical
O	255	267	observations
O	268	272	have
O	273	282	suggested
O	283	287	that
O	288	292	CICI
O	293	296	can
O	297	299	be
O	300	308	mediated
O	309	311	by
O	312	324	chemotherapy
O	324	325	-
O	325	332	induced
O	333	339	plasma
O	340	347	protein
O	348	357	oxidation
O	357	358	,
O	359	364	which
O	365	373	triggers
O	374	377	TNF
O	377	378	-
O	378	379	α
O	380	388	mediated
O	389	392	CNS
O	393	399	damage
O	399	400	.

O	401	405	This
O	406	411	study
O	412	421	evaluated
O	422	428	sodium
O	428	429	-
O	429	430	2
O	430	431	-
O	431	445	mercaptoethane
O	446	455	sulfonate
O	456	457	(
O	457	462	Mesna
O	462	463	)
O	464	466	co
O	466	467	-
O	467	481	administration
O	482	486	with
O	487	498	doxorubicin
O	499	501	to
O	502	508	reduce
O	509	520	doxorubicin
O	520	521	-
O	521	528	induced
O	529	535	plasma
O	536	543	protein
O	544	553	oxidation
O	554	557	and
O	558	567	resultant
O	568	575	cascade
O	576	578	of
O	579	582	TNF
O	582	583	-
O	583	584	α
O	584	585	,
O	586	593	soluble
O	594	597	TNF
O	598	606	receptor
O	607	613	levels
O	614	617	and
O	618	625	related
O	626	635	cytokines
O	635	636	.

B-total-participants	637	643	Thirty
I-total-participants	643	644	-
I-total-participants	644	647	two
O	648	657	evaluable
O	658	666	patients
O	667	671	were
O	672	682	randomized
O	683	688	using
O	689	690	a
O	691	700	crossover
O	701	707	design
O	708	710	to
O	711	718	receive
O	719	724	mesna
O	725	727	or
B-control	728	734	saline
O	735	737	in
O	738	744	either
O	745	748	the
O	749	754	first
O	755	757	or
O	758	764	second
O	765	770	cycle
O	771	773	of
O	774	785	doxorubicin
O	786	788	in
O	789	792	the
O	793	800	context
O	801	803	of
O	804	805	a
O	806	814	standard
O	815	827	chemotherapy
O	828	835	regimen
O	836	839	for
O	840	846	either
O	847	850	non
O	850	851	-
O	851	858	Hodgkin
O	859	867	lymphoma
O	868	870	or
O	871	877	breast
O	878	884	cancer
O	884	885	.

O	886	891	Mesna
O	892	893	(
O	893	896	360
O	897	899	mg
O	899	900	/
O	900	902	m2
O	902	903	)
O	904	906	or
O	907	913	saline
O	914	928	administration
O	929	937	occurred
O	938	940	15
O	941	948	minutes
O	949	954	prior
O	955	958	and
O	959	964	three
O	965	970	hours
O	971	975	post
O	976	987	doxorubicin
O	987	988	.

O	989	992	Pre
O	992	993	-
O	993	1002	treatment
O	1003	1006	and
O	1007	1011	post
O	1011	1012	-
O	1012	1021	treatment
O	1022	1034	measurements
O	1035	1037	of
O	1038	1047	oxidative
O	1048	1054	stress
O	1054	1055	,
O	1056	1059	TNF
O	1059	1060	-
O	1060	1061	α
O	1062	1065	and
O	1066	1073	related
O	1074	1083	cytokines
O	1084	1088	were
O	1089	1098	evaluated
O	1099	1105	during
O	1106	1109	the
O	1110	1113	two
O	1114	1126	experimental
O	1127	1133	cycles
O	1134	1136	of
O	1137	1149	chemotherapy
O	1149	1150	.

O	1151	1153	Co
O	1153	1154	-
O	1154	1168	administration
O	1169	1171	of
O	1172	1177	mesna
O	1178	1182	with
O	1183	1195	chemotherapy
O	1196	1203	reduced
O	1204	1208	post
O	1208	1209	-
O	1209	1218	treatment
B-outcome	1219	1225	levels
I-outcome	1226	1228	of
I-outcome	1229	1232	TNF
I-outcome	1232	1233	-
I-outcome	1233	1240	related
I-outcome	1241	1250	cytokines
I-outcome	1251	1254	and
I-outcome	1255	1258	TNF
I-outcome	1258	1259	-
I-outcome	1259	1267	receptor
I-outcome	1268	1269	1
I-outcome	1270	1271	(
I-outcome	1271	1276	TNFR1
I-outcome	1276	1277	)
I-outcome	1278	1281	and
I-outcome	1282	1285	TNF
I-outcome	1285	1286	-
I-outcome	1286	1294	receptor
I-outcome	1295	1296	2
O	1297	1298	(
O	1298	1303	TNFR2
O	1303	1304	)
O	1305	1306	(
O	1306	1307	p
O	1308	1309	=
O	1310	1311	0
O	1311	1312	.
O	1312	1314	05
O	1315	1318	and
O	1319	1320	p
O	1321	1322	=
O	1323	1324	0
O	1324	1325	.
O	1325	1328	002
O	1328	1329	,
O	1330	1342	respectively
O	1342	1343	)
O	1343	1344	.

O	1345	1353	Patients
O	1354	1358	with
O	1359	1362	the
O	1363	1370	highest
O	1371	1374	pre
O	1374	1375	-
O	1375	1384	treatment
O	1385	1391	levels
O	1392	1394	of
O	1395	1399	each
O	1400	1408	cytokine
O	1409	1412	and
O	1413	1416	its
O	1417	1426	receptors
O	1427	1431	were
O	1432	1435	the
O	1436	1440	most
O	1441	1447	likely
O	1448	1450	to
O	1451	1458	benefit
O	1459	1463	from
O	1464	1469	mesna
O	1470	1472	co
O	1472	1473	-
O	1473	1487	administration
O	1487	1488	.

O	1489	1492	The
O	1493	1506	extracellular
O	1507	1511	anti
O	1511	1512	-
O	1512	1519	oxidant
O	1520	1525	mesna
O	1525	1526	,
O	1527	1531	when
O	1532	1534	co
O	1534	1535	-
O	1535	1547	administered
O	1548	1554	during
O	1555	1556	a
O	1557	1563	single
O	1564	1569	cycle
O	1570	1572	of
O	1573	1584	doxorubicin
O	1584	1585	,
O	1586	1593	reduced
B-outcome	1594	1600	levels
I-outcome	1601	1603	of
I-outcome	1604	1607	TNF
I-outcome	1607	1608	-
I-outcome	1608	1609	α
I-outcome	1610	1613	and
I-outcome	1614	1617	its
I-outcome	1618	1627	receptors
O	1628	1633	after
O	1634	1638	that
O	1639	1644	cycle
O	1645	1647	of
O	1648	1655	therapy
O	1655	1656	,
O	1657	1670	demonstrating
O	1671	1674	for
O	1675	1678	the
O	1679	1684	first
O	1685	1689	time
O	1690	1691	a
O	1692	1700	clinical
O	1701	1712	interaction
O	1713	1720	between
O	1721	1726	mesna
O	1727	1730	and
O	1731	1742	doxorubicin
O	1742	1743	,
O	1744	1749	drugs
O	1750	1755	often
O	1756	1770	coincidentally
O	1771	1773	co
O	1773	1774	-
O	1774	1786	administered
O	1787	1789	in
O	1790	1795	multi
O	1795	1796	-
O	1796	1801	agent
O	1802	1810	regimens
O	1810	1811	.

O	1812	1817	These
O	1818	1826	findings
O	1827	1834	support
O	1835	1842	further
O	1843	1856	investigation
O	1857	1859	to
O	1860	1869	determine
O	1870	1877	whether
O	1878	1888	rationally
O	1888	1889	-
O	1889	1894	timed
O	1895	1900	mesna
O	1901	1903	co
O	1903	1904	-
O	1904	1918	administration
O	1919	1923	with
O	1924	1929	redox
O	1930	1936	active
O	1937	1949	chemotherapy
O	1950	1953	may
O	1954	1961	prevent
O	1962	1964	or
O	1965	1971	reduce
O	1972	1975	the
O	1976	1983	cascade
O	1984	1986	of
O	1987	1993	events
O	1994	1998	that
O	1999	2003	lead
O	2004	2006	to
O	2007	2011	CICI
O	2011	2012	.
O	2013	2027	clinicaltrials
O	2027	2028	.
O	2028	2031	gov
O	2032	2043	NCT01205503
O	2043	2044	.
